OKYO Pharma (FRA:OK10) Other Financing: €1.58 Mil (TTM As of Sep. 2025)


FRA:OK10 OKYO Pharma Ltd FRA:OK10
23 GF Score
Price €1.36
! 3 Warning Signs
View Full Analysis

What is OKYO Pharma Other Financing?

OKYO Pharma FRA:OK10 23 Other Financing is €1.58 Mil as of Sep. 2025. GuruFocus rates FRA:OK10 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

OKYO Pharma's Other Financing for the six months ended in Sep. 2025 was €0.00 Mil.

OKYO Pharma's Other Financing for the trailing twelve months (TTM) ended in Sep. 2025 was €1.58 Mil.

OKYO Pharma Other Financing Historical Data

* Premium members only.

The historical data trend for OKYO Pharma's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OKYO Pharma Other Financing Chart

OKYO Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.00 0.00 0.00 0.00

OKYO Pharma Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 1.58 0.00
FRA:OK10
23GF Score
OKYO Pharma Ltd FRA:OK10
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OKYO Pharma Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €1.58 Mil mean?
OKYO Pharma (FRA:OK10) has a Other Financing of €1.58 Mil as of Sep. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for OKYO Pharma and its competitors.
Is OKYO Pharma's Other Financing too high?
OKYO Pharma's current Other Financing is €1.58 Mil. Overall, OKYO Pharma has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does OKYO Pharma's Other Financing compare to ENTX and HRTX?
OKYO Pharma's Other Financing of €1.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for OKYO Pharma and its competitors. OKYO Pharma's current Other Financing is €1.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OKYO Pharma stock overvalued right now?
OKYO Pharma (FRA:OK10) has a current Other Financing of €1.58 Mil. The current Other Financing is €1.58 Mil. OKYO Pharma's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For OKYO Pharma (FRA:OK10), the current Other Financing is €1.58 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OKYO Pharma Business Description

Other Exchanges OKYO:USA
Address 14/15 Conduit Street, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
23GF Score

Get the complete analysis for FRA:OK10

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.36
Price